[Form 4] Health Catalyst, Inc Insider Trading Activity

Rhea-AI Filing Summary

Accenture plc (ACN) – Form 144 filing: The notice discloses that Julie Sweet intends to sell 2,251 Class A ordinary shares through UBS Financial Services on or about 11 July 2025. The aggregate market value of the planned sale is $646,509.71. During the last three months, Sweet sold 13,574 shares in three separate transactions, generating $4.997 million in gross proceeds. The proposed sale represents less than 0.001% of Accenture’s 680.3 million shares outstanding. The shares being sold were acquired via stock-award grants on 5 December 2023 (2,136 shares) and 5 January 2024 (115 shares). No other financial metrics or company-wide developments are provided in this filing.

Positive

• None.

Negative

• CEO insider selling totaling approximately $5 million year-to-date may raise sentiment concerns for some investors, despite representing a negligible fraction of shares outstanding.

Insights

Insider-Trading Analyst

TL;DR: CEO plans minor sale of 2,251 shares; immaterial to float, routine diversification.

The Form 144 reveals Julie Sweet’s intention to dispose of 2,251 Accenture Class A shares worth roughly $0.65 million. Coupled with 13,574 shares already sold since January, her total 2025 sales reach about $5 million. Although insider transactions by a CEO draw attention, the volumes are negligible relative to Accenture’s 680 million shares outstanding. No indication of undisclosed negative information is asserted, and the shares were acquired via routine stock awards. From a governance and signal-value standpoint, this appears to be a standard liquidity move rather than a material red flag.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith S. Dawn

(Last) (First) (Middle)

C/O HEALTH CATALYST, INC.

10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UT 84095

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2025		A		36,231(1)	A	$0.00	101,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, the RSUs will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next Annual Meeting of the Issuer's Stockholders.

Remarks:

	/s/Benjamin Landry, as Attorney-in-Fact	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Accenture (ACN) shares is Julie Sweet planning to sell?

She filed to sell 2,251 Class A ordinary shares.

What is the market value of the proposed sale in the Form 144?

The aggregate market value is $646,509.71.

When is the approximate sale date for the shares?

The filing lists an approximate sale date of 11 July 2025.

How many Accenture shares has Julie Sweet sold in the past three months?

She sold 13,574 shares in three prior transactions.

What percentage of Accenture’s outstanding shares does the planned sale represent?

Less than 0.001% of the 680.3 million shares outstanding.